Press Releases

August 6, 2019
MONTREAL and CHARLOTTE, N.C. , Aug. 6, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it will host a
Displaying 1 - 10 of 12
Print Page
RSS Feeds
Email Alerts
Investor Contact
Search